Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Kisqali“
Suchtreffer
Begriffe & Kennungen
Kisqali · 4.8 Undesirable effects · 1
Eintrag öffnenKisqali · 4.8 · 13 based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/
Eintrag öffnenKisqali · 4.8 · 14 Investigations Very common Abnormal liver function tests6 Abnormal liver function tests6 Common Blood creat
Eintrag öffnenKisqali · 4.8 · 15 Dose interruptions due to hepatobiliary toxicity events were reported in 12.4% of patients with early breas
Eintrag öffnenKisqali · 4.8 · 16 In study E2301 (MONALEESA-7) in patients with advanced or metastatic breast cancer, the observed mean QTcF
Eintrag öffnenKisqali · 4.8 · A central analysis of ECG data showed 10 patients (0.4%) and 4 patients (0.2%) with at least one post- baselin
Eintrag öffnenKisqali · 4.8 · ADRs from the phase III clinical studies and post-marketing experience (Table 7) in patients with early breast
Eintrag öffnenKisqali · 4.8 · Advanced or metastatic breast cancer The most common adverse drug reactions (ADRs) (reported at a frequency ≥2
Eintrag öffnenKisqali · 4.8 · Advanced or metastatic breast cancer The overall safety evaluation of Kisqali is based on the pooled dataset f
Eintrag öffnenKisqali · 4.8 · All patients should be instructed to report any fever promptly.
Eintrag öffnenKisqali · 4.8 · Among the patients with advanced or metastatic breast cancer who had grade 2, 3 or 4 neutropenia, the median t
Eintrag öffnenKisqali · 4.8 · Among the patients with early breast cancer who had grade 2, 3 or 4 neutropenia, the median time to onset was
Eintrag öffnenKisqali · 4.8 · Description of selected adverse reactions
Eintrag öffnenKisqali · 4.8 · Dose interruptions and/or adjustments due to hepatobiliary toxicity events were reported in 12.3% of Kisqali p
Eintrag öffnenKisqali · 4.8 · Dose reduction due to adverse events, regardless of causality, occurred in 22.8% of patients receiving Kisqali
Eintrag öffnenKisqali · 4.8 · Dose reduction due to adverse events, regardless of causality, occurred in 39.5% of patients receiving Kisqali
Eintrag öffnenKisqali · 4.8 · Early breast cancer The most common adverse drug reactions (ADRs) (reported at a frequency ≥20%) in the datase
Eintrag öffnenKisqali · 4.8 · Early breast cancer The overall safety evaluation of Kisqali is based on the dataset from 2 525 patients who r
Eintrag öffnenKisqali · 4.8 · Frequency Patients with early breast cancer Patients with advanced or with starting dose 400 mg ribociclib met
Eintrag öffnenKisqali · 4.8 · Hepatobiliary toxicity In the phase III clinical studies in patients with early breast cancer and advanced or
Eintrag öffnen